Cargando…

High frequency of Plasmodium falciparum chloroquine resistance marker (pfcrt T76 mutation) in Yemen: An urgent need to re-examine malaria drug policy

BACKGROUND: Malaria remains a significant health problem in Yemen with Plasmodium falciparum being the predominant species which is responsible for 90% of the malaria cases. Despite serious concerns regarding increasing drug resistance, chloroquine is still used for the prevention and treatment of m...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Mekhlafi, Abdulsalam M, Mahdy, Mohammed AK, Al-Mekhlafi, Hesham M, Azazy, Ahmed A, Fong, Mun Yik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3125383/
https://www.ncbi.nlm.nih.gov/pubmed/21619624
http://dx.doi.org/10.1186/1756-3305-4-94
_version_ 1782207220509835264
author Al-Mekhlafi, Abdulsalam M
Mahdy, Mohammed AK
Al-Mekhlafi, Hesham M
Azazy, Ahmed A
Fong, Mun Yik
author_facet Al-Mekhlafi, Abdulsalam M
Mahdy, Mohammed AK
Al-Mekhlafi, Hesham M
Azazy, Ahmed A
Fong, Mun Yik
author_sort Al-Mekhlafi, Abdulsalam M
collection PubMed
description BACKGROUND: Malaria remains a significant health problem in Yemen with Plasmodium falciparum being the predominant species which is responsible for 90% of the malaria cases. Despite serious concerns regarding increasing drug resistance, chloroquine is still used for the prevention and treatment of malaria in Yemen. This study was carried out to determine the prevalence of choloroquine resistance (CQR) of P. falciparum isolated from Yemen based on the pfcrt T76 mutation. METHODS: A cross-sectional study was carried out among 511 participants from four governorates in Yemen. Blood samples were screened using microscopic and species-specific nested PCR based on the 18S rRNA gene to detect and identify Plasmodium species. Blood samples positive for P. falciparum were used for detecting the pfcrt T76 mutation using nested-PCR. RESULTS: The prevalence of pfcrt T76 mutation was 81.5% (66 of 81 isolates). Coastal areas/foothills had higher prevalence of pfcrt T76 mutation compared to highland areas (90.5% vs 71.8%) (p = 0.031). The pfcrt T76 mutation had a significant association with parasitaemia (p = 0.045). Univariate analysis shows a significant association of pfcrt T76 mutation with people aged > 10 years (OR = 9, 95% CI = 2.3 - 36.2, p = 0.001), low household income (OR = 5, 95% CI = 1.3 - 19.5, p = 0.027), no insecticide spray (OR = 3.7, 95% CI = 1.16 - 11.86, p = 0.025) and not sleeping under insecticide treated nets (ITNs) (OR = 4.8, 95% CI = 1.38 - 16.78, p = 0.01). Logistic regression model confirmed age > 10 years and low household income as predictors of pfcrt T76 mutation in Yemen P. falciparum isolates. CONCLUSIONS: The high prevalence of pfcrt T76 mutation in Yemen could be a predictive marker for the prevalence of P. falciparum CQR. This finding shows the necessity for an in-vivo therapeutic efficacy test for CQ. P. falciparum CQR should be addressed in the national strategy to control malaria.
format Online
Article
Text
id pubmed-3125383
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31253832011-06-29 High frequency of Plasmodium falciparum chloroquine resistance marker (pfcrt T76 mutation) in Yemen: An urgent need to re-examine malaria drug policy Al-Mekhlafi, Abdulsalam M Mahdy, Mohammed AK Al-Mekhlafi, Hesham M Azazy, Ahmed A Fong, Mun Yik Parasit Vectors Research BACKGROUND: Malaria remains a significant health problem in Yemen with Plasmodium falciparum being the predominant species which is responsible for 90% of the malaria cases. Despite serious concerns regarding increasing drug resistance, chloroquine is still used for the prevention and treatment of malaria in Yemen. This study was carried out to determine the prevalence of choloroquine resistance (CQR) of P. falciparum isolated from Yemen based on the pfcrt T76 mutation. METHODS: A cross-sectional study was carried out among 511 participants from four governorates in Yemen. Blood samples were screened using microscopic and species-specific nested PCR based on the 18S rRNA gene to detect and identify Plasmodium species. Blood samples positive for P. falciparum were used for detecting the pfcrt T76 mutation using nested-PCR. RESULTS: The prevalence of pfcrt T76 mutation was 81.5% (66 of 81 isolates). Coastal areas/foothills had higher prevalence of pfcrt T76 mutation compared to highland areas (90.5% vs 71.8%) (p = 0.031). The pfcrt T76 mutation had a significant association with parasitaemia (p = 0.045). Univariate analysis shows a significant association of pfcrt T76 mutation with people aged > 10 years (OR = 9, 95% CI = 2.3 - 36.2, p = 0.001), low household income (OR = 5, 95% CI = 1.3 - 19.5, p = 0.027), no insecticide spray (OR = 3.7, 95% CI = 1.16 - 11.86, p = 0.025) and not sleeping under insecticide treated nets (ITNs) (OR = 4.8, 95% CI = 1.38 - 16.78, p = 0.01). Logistic regression model confirmed age > 10 years and low household income as predictors of pfcrt T76 mutation in Yemen P. falciparum isolates. CONCLUSIONS: The high prevalence of pfcrt T76 mutation in Yemen could be a predictive marker for the prevalence of P. falciparum CQR. This finding shows the necessity for an in-vivo therapeutic efficacy test for CQ. P. falciparum CQR should be addressed in the national strategy to control malaria. BioMed Central 2011-05-27 /pmc/articles/PMC3125383/ /pubmed/21619624 http://dx.doi.org/10.1186/1756-3305-4-94 Text en Copyright ©2011 Al-Mekhlafi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Al-Mekhlafi, Abdulsalam M
Mahdy, Mohammed AK
Al-Mekhlafi, Hesham M
Azazy, Ahmed A
Fong, Mun Yik
High frequency of Plasmodium falciparum chloroquine resistance marker (pfcrt T76 mutation) in Yemen: An urgent need to re-examine malaria drug policy
title High frequency of Plasmodium falciparum chloroquine resistance marker (pfcrt T76 mutation) in Yemen: An urgent need to re-examine malaria drug policy
title_full High frequency of Plasmodium falciparum chloroquine resistance marker (pfcrt T76 mutation) in Yemen: An urgent need to re-examine malaria drug policy
title_fullStr High frequency of Plasmodium falciparum chloroquine resistance marker (pfcrt T76 mutation) in Yemen: An urgent need to re-examine malaria drug policy
title_full_unstemmed High frequency of Plasmodium falciparum chloroquine resistance marker (pfcrt T76 mutation) in Yemen: An urgent need to re-examine malaria drug policy
title_short High frequency of Plasmodium falciparum chloroquine resistance marker (pfcrt T76 mutation) in Yemen: An urgent need to re-examine malaria drug policy
title_sort high frequency of plasmodium falciparum chloroquine resistance marker (pfcrt t76 mutation) in yemen: an urgent need to re-examine malaria drug policy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3125383/
https://www.ncbi.nlm.nih.gov/pubmed/21619624
http://dx.doi.org/10.1186/1756-3305-4-94
work_keys_str_mv AT almekhlafiabdulsalamm highfrequencyofplasmodiumfalciparumchloroquineresistancemarkerpfcrtt76mutationinyemenanurgentneedtoreexaminemalariadrugpolicy
AT mahdymohammedak highfrequencyofplasmodiumfalciparumchloroquineresistancemarkerpfcrtt76mutationinyemenanurgentneedtoreexaminemalariadrugpolicy
AT almekhlafiheshamm highfrequencyofplasmodiumfalciparumchloroquineresistancemarkerpfcrtt76mutationinyemenanurgentneedtoreexaminemalariadrugpolicy
AT azazyahmeda highfrequencyofplasmodiumfalciparumchloroquineresistancemarkerpfcrtt76mutationinyemenanurgentneedtoreexaminemalariadrugpolicy
AT fongmunyik highfrequencyofplasmodiumfalciparumchloroquineresistancemarkerpfcrtt76mutationinyemenanurgentneedtoreexaminemalariadrugpolicy